Details of the Drug Combination

General Information of Drug Combination (ID: DCPTV8N)

Drug Combination Name
Picoplatin ER819762
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 ER819762   DMSG91J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: OVCAR-4
Zero Interaction Potency (ZIP) Score: 3.09
Bliss Independence Score: 3.44
Loewe Additivity Score: 0.03
LHighest Single Agent (HSA) Score: 0.03

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Small-cell lung cancer 2C25.Y Phase 3 [2]
Indication(s) of ER819762
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
ER819762 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Glioma DC01GS5 SF-268 Investigative [5]
Adenocarcinoma DCT728J OVCAR3 Investigative [1]
Adenocarcinoma DC0DRA3 NCIH23 Investigative [1]
Adenocarcinoma DC6UT62 HCT-15 Investigative [1]
Lung adenocarcinoma DCKU36B HOP-62 Investigative [1]
Minimally invasive lung adenocarcinoma DCPYCTU NCI-H322M Investigative [1]
Prostate carcinoma DCIKLYZ PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4 A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966